drugset

drugset / Trial / NCT00125294

Sublingual Methadone for the Management of Cancer Breakthrough Pain

NCT00125294 ↗

Phase 1 Completed 10 enrolled AHS Cancer Control Alberta Calgary Health Region · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.

Timeline

Start: 2003-09
Primary completion: 2006-06
Completion: 2007-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methadone	Other / unclassified	—	Other

Indications